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Aims Innate mechanisms of inter-organ protection underlie the phenomenon of remote ischaemic preconditioning (RPc) in
which episode(s) of ischaemia and reperfusion in tissues remote from the heart reduce myocardial ischaemia/reperfusion
injury. The uncertainty surrounding the mechanism(s) underlying RPc centres on whether humoral factor(s) produced
during ischaemia/reperfusion of remote tissue and released into the systemic circulation mediate RPc, or whether a
neural signal is required. While these two hypotheses may not be incompatible, one approach to clarify the potential
role of a neural pathway requires targeted disruption or activation of discrete central nervous substrate(s).
Methods
and results
Using a rat model of myocardial ischaemia/reperfusion injury in combination with viral gene transfer, pharmaco-, and
optogenetics, we tested the hypothesis that RPc cardioprotection depends on the activity of vagal pre-ganglionic neu-
rones and consequently an intact parasympathetic drive. For cell-specific silencing or activation, neurones of the
brainstem dorsal motor nucleus of the vagus nerve (DVMN) were targeted using viral vectors to express a Drosophila
allatostatin receptor (AlstR) or light-sensitive fast channelrhodopsin variant (ChIEF), respectively. RPc cardioprotec-
tion, elicited by ischaemia/reperfusion of the limbs, was abolished when DVMN neurones transduced to express
AlstR were silenced by selective ligand allatostatin or in conditions of systemic muscarinic receptor blockade with
atropine. In the absence of remote ischaemia/reperfusion, optogenetic activation of DVMN neurones transduced
to express ChIEF reduced infarct size, mimicking the effect of RPc.
Conclusion These data indicate a crucial dependence of RPc cardioprotection against ischaemia/reperfusion injury upon the ac-
tivity of a distinct population of vagal pre-ganglionic neurones.
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1. Introduction
Our body is capable of recruiting powerful innate mechanisms that
are highly effective in protecting tissues and organ function against is-
chaemia/reperfusion injury. A landmark study by Murry et al.1 demon-
strated that the exposure of the myocardium to short non-lethal
ischaemia-reperfusion episodes renders it more tolerant to subse-
quent severe, potentially lethal, periods of ischaemia, i.e. the heart
becomes ‘preconditioned’. A similar level of protection can be
achieved by remote ischaemic preconditioning (RPc)—a phenomenon
in which episode(s) of ischaemia and reperfusion in tissues remote
from the heart protect the myocardium against ischaemia/reperfusion
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injury. Although, promising results of recent trials in patients with
acute myocardial infarction2 may facilitate the introduction of RPc
procedure(s) into clinical practice, the mechanisms underlying RPc
cardioprotection remain unclear.
The importance of the autonomic nervous system in mediating
myocardial protection against ischaemia/reperfusion injury has been
suggested by the demonstration that RPc is abolished under ganglionic
blockade following systemic administration of hexamethonium,3
which blocks transmission in both sympathetic and parasympathetic
ganglia. Vagus nerve stimulation reduces myocardial injury,4–6 while
RPc cardioprotection was found to be abolished in conditions of bi-
lateral vagotomy.7,8 These data suggest that an intact parasympathetic
activity is important for RPc cardioprotection. However, the vagus is a
mixed nerve containing both sensory and motor fibres. Therefore, to
avoid confounding factors associated with complete surgical vagot-
omy or electrical stimulation of the whole nerve, selective vagal
‘de-efferentation’ or selective recruitment of vagal motor outflow
require cell-specific targeting of vagal pre-ganglionic neurones. In
this study, we used pharmaco- and optogenetic approaches to test
the hypothesis that the functional integrity of the central nervous
parasympathetic circuitry is required for myocardial protection estab-
lished by ischaemia/reperfusion stimulus applied to a remote tissue.
2. Methods
All the experiments were performed in accordance with the European
Commission Directive 86/609/EEC (European Convention for the Protec-
tion of Vertebrate Animals used for Experimental and Other Scientific
Purposes) and the UK Home Office (Scientific Procedures) Act (1986)
with project approval from the Institutional Animal Care and Use
Committee.
2.1 Animal preparation
Adult male Sprague-Dawley rats (280–340 g) were anaesthetised with
pentobarbitone sodium (induction 60 mg kg21 ip; maintenance 10–
15 mg kg21 h21 iv). Adequate anaesthesia was ensured by monitoring
heart rate, arterial blood pressure, and the absence of a withdrawal re-
sponse to a paw pinch. Animals were placed supine and a right carotid
artery and left jugular vein cannulated for the measurement of arterial
blood pressure and the administration of anaesthetic, respectively. The
trachea was cannulated and animals were ventilated with room air using
a positive pressure ventilator (Harvard Rodent Ventilator). A tidal
volume of 8–10 mL kg21 and a ventilator frequency similar to the
normal respiratory frequency (60 strokes min21) were used. Partial
pressures of O2 and CO2 as well as pH of the arterial blood were mea-
sured every hour. The rate and volume of mechanical ventilation were
adjusted to maintain blood gases within the physiological range. Standard
lead II ECG was recorded throughout the experiment. Body temperature
was maintained with a servo-controlled heating pad at 37.0+0.28C.
2.2 Induction of RPc
To establish RPc cardioprotection, the protocol described by Shahid
et al.9 was used. Blood supply to the limbs was interrupted for 15 min
by placing vessel clamps on both femoral arteries at the proximal level
1 cm below the inguinal ligament. The Sham-RPc procedure involved
dissection of both femoral arteries without occlusion.
2.3 Myocardial ischaemia/reperfusion
The heart was exposed via a left thoracotomy. A 5-0 monofilament poly-
propylene suture was passed around the left anterior descending (LAD)
coronary artery to induce a temporary occlusion. The animals were
subjected to 30 min of LAD coronary artery ligation, followed by
120 min of reperfusion. Successful coronary artery occlusion was con-
firmed by elevation of the ST-segment in the ECG and an immediate
15–30 mmHg fall in arterial blood pressure.
2.4 Measurements of infarct size
At the end of the reperfusion period, the LAD artery was re-occluded and
1 mL of 1.5% Evans blue dye was injected into the jugular vein for the as-
sessment of the area at risk. The animal was then given an anaesthetic
overdose (pentobarbital 250 mg kg21 iv), the heart was excised, left ven-
tricle was isolated, frozen, and sectioned into five to six transverse slices
from the apex to the base. The slices were weighed and photographed.
The area at risk was demarcated by the absence of Evans blue staining.
The slices were then incubated with 1% 2,3,5-triphenyltetrasodium chlor-
ide (TTC) in Tris buffer (pH 7.4) for 15 min at 378C, fixed in 4% formalin
for 24 h, and photographed again. Viable myocardium is stained red by
TTC, whereas necrotic myocardium appears pale yellow. The area at
risk and the necrotic area were determined by computerized planimetry,
normalized to the weight of each slice, with degree of necrosis (i.e. infarct
size) expressed as the percentage of area at risk.
2.5 Targeting vagal pre-ganglionic neurones
with viral vectors
Cholinergic vagal pre-ganglionic neurones of the dorsal motor nucleus of
the vagus nerve (DVMN) express the transcriptional factor, Phox2, and
were targeted using an artificial Phox2-activated promoter—PRSx810—
incorporated into lenti- and adenoviral vectors (AVs).11 Expression
driven by PRSx8 is dependent on the activity of Phox2 and, therefore, ex-
pression in DVMN neurones is not surprising, given the putative role of
Phox2 in the development of these neurones.12
The lentiviral construct used to express the Gi-protein-coupled Dros-
ophila allatostatin receptor (AlstR) in DVMN neurones has been described
previously.13,14 In brief, the plasmid pTYF-PRSx8-AlstR-IRES2-eGFP
(enhanced green fluorescent protein) was used to generate the lentiviral
vector (LV). The LV system used was HIV-1-derived and pseudotyped
with the VSV-G envelope.15 Titres of PRSx8-AlstR-eGFP-LV and the
control vector (PRSx8-eGFP-LV) were between 1 × 109 and 1 × 1010
transducing units mL21. Viral concentration and titration were carried
out as described in detail previously.15
To control the activity of DVMN neurones with high temporal reso-
lution, we generated a new AV where a mutant of channelrhodopsin
(ChR)—ChIEF—is fused with a red fluorescent protein—the tandem
dimer Tomato (tdTomato) protein. The ChIEFtdTomato clone was
kindly provided by Dr JY Lin (University of California). ChIEF is a chimeric
ChR variant constructed from the N-terminal part of the ChR1 and the
C-terminal part of the ChR2 and also incorporates an isoleucine 170 to
valine mutation. ChIEF combines the reduced inactivation characteristics
of ChR1 with more favourable cation permeability properties conferred
by ChR2.16 The I170V mutation further improves the channel closure
kinetics. Therefore, ChIEF allows a greater temporal control of neuronal
activation by light pulses. Its spectral properties are similar to those of
ChR2 but it shows more efficient membrane expression and trafficking
in the mammalian cells.16
In this study, ChIEFtdTomato was engineered into an AV under the
control of an enhanced17,18 PRSx8 promoter.10,11 AVs were produced
as described previously.19,20
2.6 Viral gene transfer
Rats were anaesthetized [ketamine (60 mg kg21; im) and medetomidine
(250 mg kg21, im)] and placed in a stereotaxic frame. Adequate surgical
anaesthesia was ensured by the absence of a withdrawal response to a
paw pinch. DVMN neurones were targeted with two microinjections
per side (0.25 mL each, 0.05 mL min21) of a viral suspension containing
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PRSx8-AlstR-eGFP-LV, PRSx8-eGFP-LV, PRSx8-ChIEFtdTomato-AV, or
PRSx8-DsRed-AV (control for optogenetic experiments; this vector
drives the expression of DsRed in the DVMN neurones). The PRSx8 pro-
moter is also active in a population of noradrenergic neurones (A2 cell
group) of the nucleus of the solitary tract located dorsal to the
DVMN.21 To avoid transduction of A2 neurones, injections were placed
immediately ventral to the DVMN using the following coordinates from
calamus scriptorius (i) 0.5 mm rostral, 0.6 mm lateral, 0.8 mm ventral and
(ii) 1.0 mm rostral, 0.8 mm lateral, 0.6 mm ventral. In our preliminary val-
idation experiments conducted in six animals, along with widespread ex-
pression of the transgene in the DVMN, we only found occasional (2–5
per brainstem) neurones expressing ChIEFtdTomato and stained positive
for the noradrenergic marker DBH. Similarly, in contrast to strong AlstR
expression in almost the entire population of DVMN neurones, the ma-
jority of dorsally located noradrenergic neurones were not transduced
(Figure 1A and B). Thus, precise stereotaxic targeting of the viral vector
ensured specific transduction of DVMN neurones. Anaesthesia was
reversed with atipemazole (1 mg kg21) and no complications were
observed after the surgery.
2.7 In vitro electrophysiology: verification of
transgene functionality
Rapid inhibitory and readily reversible effects of allatostatin were previ-
ously reported to be selective for AlstR-expressing neurones.22 Binding
of an allatostatin peptide to AlstR23 should lead to opening of inwardly
rectifying K+ channels, neuronal hyperpolarization, and cessation of
action potential firing.22,24 Naturally, AlstRs are only expressed in
insects and allatostatin itself does not interfere with endogenous receptor
complexes in mammals.22,23 Conversely, the activation of ChIEFtdTomato
using blue light should lead to immediate neuronal depolarization and
action potential firing. Visually guided patch-clamp recordings in the brain-
stem slice preparation were used to verify the efficacy of these
approaches in silencing and activating DVMN neurones, respectively.
Seven to ten days after the delivery of PRSx8-AlstR-eGFP-LV or
PRSx8-ChIEFtdTomato-AV into the DVMN, rats were sacrificed with
halothane overdose and 200-mm coronal brainstem slices were cut and
maintained as described previously.25 Patch pipettes (3–6 MV) were
pulled from thin-walled borosilicate capillary glass (Clark Electromedical
Instruments, Pangbourne, UK). Electrodes were filled with (in millimolar)
120 K-gluconate, 5 HEPES, 5 BAPTA, 1 NaCl, 1 MgCl2, 1 CaCl2, 2 K2ATP
(pH 7.2). Recordings were carried out under an epifluorescence micro-
scope (Zeiss Axioskop 2 FS, Zeiss, Germany) in artificial cerebrospinal
fluid (aCSF, containing in millimolar; 118 NaCl, 3 KCl, 25 NaHCO3, 1
MgCl2, 2 CaCl2, and 10 glucose) saturated with 95% O2/5% CO2 (pH
7.4) at 28–328C. The recording chamber (volume 2 mL) was perfused
with aCSF at a rate of 4–5 mL min21. Recordings were performed in
cell attached configuration and whole-cell mode using an EPC-9 amplifier
and Pulse/Pulsefit software (Heka Elektronik, Lambrecht, Germany). Cur-
rents or membrane potentials were filtered at 1 kHz and digitized at
3 kHz.
DVMN neurones expressing AlstR were identified by eGFP fluores-
cence. To test neuronal responses to activation of AlstR, allatostatin
(0.5–1 mM; Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2, Phoenix Pharmaceu-
ticals, USA) was added to the perfusate. For recordings from the DVMN
neurones expressing ChIEFtdTomato, cells were identified by red
Figure 1 Genetic targeting and silencing of vagal pre-ganglionic neurones in the dorsal motor nucleus of the vagus nerve (DVMN). (A) Confocal
image of the coronal section of the rat brainstem targeted to express allatostatin receptor (AlstR) in the DVMN. Figure illustrates a representative
example of the distribution of choline acetyltransferase (ChAT)-positive (i.e. cholinergic) (red) DVMN neurones transduced to express AlstR/eGFP
(green). Colocalization appears yellow. Bregma level 214 mm. XII, hypoglossal motor nucleus (ChAT-positive, but not expressing eGFP). CC, central
canal; (B) a representative example of the distribution of AlstR/eGFP-transduced DVMN neurones in relation to the location of A2 noradrenergic cells
identified by tyrosine hydroxylase (TH) immunohistochemistry (red). Along with strong expression of AlstR/eGFP in the DVMN only occasional nor-
adrenergic neurones were found to be transduced. Colocalization appears yellow (arrows). Bregma level 213.8 mm. (C) Representative cell-attached
recording from an AlstR/eGFP-positive DVMN neurone illustrating its rapid and reversible silencing in response to allatostatin (0.5 mM); (D) current–
voltage relationship (IV) of allatostatin-induced current. Transduced DVMN neurone was voltage-clamped to 230 mV and hyperpolarizing voltage
ramps to 2130 mV (700 ms duration) were applied before and during allatostatin application. The displayed IV was obtained by subtracting the whole-
cell IV obtained under control conditions, from that obtained in the presence of allatostatin.
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(tdTomato) fluorescence. A light fibre connected to a 445 nm laser
(Omicon, Germany) was submerged into the recording chamber and
pointed towards the slice. Duration and intensity of light pulses were con-
trolled by laser software and triggered from the EPC-9 amplifier. Control
recordings verified that neither allatostatin (n ¼ 5) nor 445 nm light (n ¼
4) had an effect on electrical activity in untransduced DVMN neurones.
2.8 Immunohistochemistry: verification of
transgene expression
At the end of the in vivo experiments, the rats transduced to express
AlstR/eGFP or ChIEFtdTomato in the DVMN neurones were perfused
through the ascending aorta with 0.9% saline solution followed by 4%
phosphate-buffered (0.1 M, pH 7.4) paraformaldehyde. After 12 h of post-
fixation and subsequent cryoprotection (30% sucrose), 30-mm-thick
coronal sections were collected along the rostro-caudal extent of the
medulla oblongata. Sections were processed for the immunohistochem-
ical detection of choline acetyl-transferase (ChAT) or tyrosine hydroxy-
lase (TH). Tissue was incubated in goat anti-ChAT (1:500, Chemicon)
or sheep anti-TH (1:250, Abcam) followed by donkey anti-goat Alexa
Fluor568 or biotinylated rabbit anti-sheep (1:500) amplified by AMCA
avidin DCS (1:250, Vector laboratories). Identification of AlstR-expressing
neurones was enhanced by eGFP immunostaining as described previous-
ly.13 All brainstem sections from this group, including those stained for
ChAT and TH, were subsequently incubated in chicken anti-GFP antibody
(1:250, Ave´s) for 48 h followed by goat anti-chicken Alexa Fluor488
(1:1000, Molecular Probes).
2.9 Experimental protocols
2.9.1 RPc in conditions of DVMN silencing
A small occipital craniotomy was performed and a miniature polyethylene
catheter was slid around the caudal surface of the cerebellum and secured
in place with dental impression material with the catheter tip placed in the
cisterna magna. All rats transduced with either PRSx8-AlstR-eGFP-LV or
PRSx8-eGFP-LV received slow continuous infusion of allatostatin
(100 mM in aCSF; 4 mL h21) starting 15 min prior to RPc or sham-RPc
procedures and lasting till the end of the myocardial ischaemia/reperfusion
period.
2.9.2 Optogenetic conditioning of the heart
Occipital craniotomy was performed and the cerebellum was partially
removed to expose the dorsal part of the medulla oblongata overlaying
dorsal vagal complex, including the DVMN. DVMN neurones were stimu-
lated using blue light (445 nm, 10 ms pulses, 10 Hz) delivered via an
optrode placed against the brainstem surface. Light stimulation com-
menced 25 min prior to myocardial ischaemia (to follow the timeline of
the RPc protocol) and lasted 10 min into the reperfusion period. Atropine
was administered (initial bolus dose 2 mg kg21 iv 15 min prior to light
onset; followed by infusion at a rate of 1 mg kg21 h21 iv) to separate
groups of animals in order to determine the effect of systemic muscarinic
receptor blockade on cardioprotection elicited by optogenetic stimula-
tion of the DVMN neurones.
2.9.3 RPc in conditions of systemic muscarinic receptor
blockade with atropine
The systemic muscarinic receptor blockade was achieved by iv infusion of
atropine methyl nitrate 15 min prior to RPc or sham-RPc procedures
(initial bolus dose 2 mg kg21 iv; followed by infusion at a rate of
1 mg kg21 h21 iv).
2.10 Statistical analysis
Data are reported as mean+ SEM. Data were compared by Kruskal–
Wallis ANOVA by ranks or Student’s t-test, as appropriate. Values of P
, 0.05 were considered to be significant.
3. Results
A LV bearing the PRSx8 promoter was highly efficient in driving the
expression of AlstR/eGFP in DVMN neurones (Figure 1A and B).
First, patch-clamp recordings in brainstem slices were used to
confirm that activation of AlstR inhibits the activity of transduced neu-
rones by opening inwardly rectifying K+ channels, hyperpolarization,
and cessation of action potential generation.22 DVMN neurones
expressing AlstR/eGFP recorded in cell-attached configuration had a
mean firing rate of 1.7+ 0.4 Hz (n ¼ 6). Application of allatostatin re-
versibly abolished action potential firing within 2 min in five cells
(Figure 1C) and decreased firing rate by 55% in one remaining cell.
In whole-cell current clamp recording configuration, allatostatin
induced a 5.3+0.8 mV hyperpolarization and cessation of firing,
caused by activation of an inwardly rectifying K+ conductance, as
revealed in voltage clamp recordings (n ¼ 4) (Figure 1D). Thus, tar-
geted stereotaxic delivery of the viral vector (avoiding transduction
of dorsally located catecholaminergic neurones, Figure 1B), the speci-
ficity of the PRSx8 promoter, and the effective silencing of transduced
AlstR-expressing neurones by allatostatin allowed the accurate assess-
ment of the functional role of DVMN vagal pre-ganglionic neurones
with high temporal resolution.
The efficacy of RPc cardioprotection was then assessed, while
DVMN neurones were inhibited by allatostatin (100 mM) continuous-
ly infused (4 mL h21) into the cisterna magna (Figure 2A). RPc induced
by ischaemia/reperfusion of the limbs reduced myocardial ischaemia/
reperfusion injury as evident from a significant (P, 0.01) reduction in
the infarct size (Figure 2B). Selective DVMN silencing abolished RPc
cardioprotection (P ¼ 0.004) while having no effect on the infarct
size in animals not subjected to RPc (Figure 2B). There were no differ-
ences in the areas at risk between groups of animals recruited into the
experimental groups. There were also no differences in mean arterial
blood pressure or heart rate between the groups of animals either
before, or during myocardial ischaemia and reperfusion (Table 1).
Thus, RPc cardioprotection appears to be crucially dependent on
the activity of DVMN neurones.
By extension, activation of DVMN neurones in the absence of
remote ischaemia/reperfusion should result in cardioprotection. To
test this hypothesis, we used optogenetics to increase DVMN neur-
onal activity with high resolution and specificity. DVMN neurones
transduced to express ChIEFtdTomato (Figure 3A and B) displayed
precisely timed depolarizations and action potential firing in response
to flashes of blue (445 nm) light (Figure 3A). Voltage clamp analysis
revealed that light stimulation induces an inward current with half
maximal activation by a 5 ms light pulse (Figure 3C). Consequently,
optogenetic stimulation of DVMN in vivo was performed with 10 ms
pulse duration at a frequency of 10 Hz (a stimulation regime not asso-
ciated with changes in heart rate or blood pressure; Table 1). Opto-
genetic stimulation of DVMN markedly reduced the infarct size
(P ¼ 0.008; Figure 3D), indicating that increased activity of this specific
neuronal population is sufficient to limit ischaemia/reperfusion myo-
cardial injury, effectively mimicking the effect of RPc. In conditions
of systemic administration of atropine optogenetic stimulation of
the DVMN neurones failed to establish cardioprotection (Figure 3D).
This observation prompted the experiment to determine whether
a muscarinic receptor mechanism mediates RPc cardioprotection. RPc
conferred no cardioprotection in conditions of the systemic muscar-
inic receptor blockade with atropine methyl nitrate (Figure 4) that has
a limited ability to cross the blood–brain barrier. Atropine had no
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effect on heart rate in animals subjected to the RPc procedure
(Table 2), consistent with the data showing that in rats, anaesthetized
with pentobarbital, chronotropic vagal tone is significantly reduced.26
4. Discussion
The present study reveals a crucial dependence of interorgan (limb-
heart) protection against ischaemia/reperfusion injury upon the
activity of a distinct population of vagal pre-ganglionic neurones resid-
ing in the DVMN. It also demonstrates for the first time that activation
of a specific central nervous substrate can effectively protect the heart
against lethal ischaemia/reperfusion injury.
Here, we tested the hypothesis that cardioprotection induced by
ischaemia/reperfusion of the remote tissue requires functional integ-
rity of the central nervous parasympathetic circuitry and, by exten-
sion, an intact parasympathetic activity. This hypothesis was based
Figure 2 Remote preconditioning (RPc) cardioprotection critically depends on the activity of DVMN vagal pre-ganglionic neurones. (A) Illustration
of the experimental protocols. RPc was induced by 15 min occlusion of both femoral arteries, followed by 10 min reperfusion. The Sham-RPc pro-
cedure involved dissection of both femoral arteries without occlusion. Arrow indicates the start of allatostatin infusion into the cisterna magna. eGFP,
animals transduced to express eGFP in the DVMN. AlstR, animals transduced to express AlstR/eGFP in the DVMN. MI, myocardial ischaemia. (B)
Silencing DVMN neurones abolishes RPc cardioprotection. The infarct size is presented as the percentage of area at risk. Individual data and means+
SEM are shown. **P, 0.01 (Kruskal–Wallis ANOVA by ranks).
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Table 1 Haemodynamic data
Variable Pre-ischaemia End ischaemia Reperfusion (min)
30 60 120
DVMN silencing experiment
DVMN neurones expressing eGFP
Allatostatin + sham-RPc (n ¼ 7) MAP 106+7 101+7 96+6 92+5 91+4
HR 408+8 411+9 389+10 393+10 405+9
Allatostatin + RPc (n ¼ 8) MAP 111+11 108+13 104+8 101+6 96+7
HR 427+8 429+10 422+8 427+9 420+10
DVMN neurones expressing AlstR
Allatostatin + sham-RPc (n ¼ 7) MAP 115+9 104+10 99+8 91+7 82+7
HR 401+9 421+13 397+12 384+12 387+13
Allatostatin + RPc (n ¼ 8) MAP 117+9 103+7 102+5 101+5 97+6
HR 413+15 430+9 405+7 407+7 409+10
Optogenetic preconditioning experiment
DsRed—DVMN blue light (n ¼ 7) MAP 92+9 82+7 78+3 77+5 80+5
HR 401+12 403+8 384+5 380+7 388+8
CHIEFtdTomato—DVMN blue light (n ¼ 6) MAP 99+6 79+4 78+4 80+5 83+4
HR 420+6 415+8 402+7 397+9 393+9
DsRed—DVMN blue light + atropine (n ¼ 7) MAP 106+11 85+5 90+4 90+7 80+7
HR 391+17 392+11 393+10 410+12 402+11
CHIEFtdTomato—DVMN blue light + atropine (n ¼ 8) MAP 99+10 76+6 84+5 79+4 71+3
HR 379+14 392+15 389+11 380+20 384+10
AlstR, allatostatin receptor; DVMN, dorsal motor nucleus of the vagus nerve; eGFP, enhanced green fluorescent protein; HR, heart rate (min21); MAP, mean arterial blood pressure
(mmHg); RPc, remote preconditioning.
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on the following earlier findings. First, RPc is abolished by systemic
hexamethonium administration,3 which blocks transmission in both
sympathetic and parasympathetic ganglia. Second, electrical stimula-
tion of the vagus nerve is cardioprotective, limits myocardial ischae-
mia/reperfusion injury,5,6 and reduces the number of severe
arrhythmias and overall lethality.4 Our recent observations also
demonstrated that RPc cardioprotection is abolished by bilateral cer-
vical vagotomy.7,8 However, while eliminating vagal efferent activity,
cervical vagotomy also interrupts the transmission of sensory infor-
mation from the heart (and other internal organs) to the CNS. To
avoid confounding factors associated with complete surgical vagot-
omy, here we performed a selective (albeit partial) vagal
‘de-efferentation’ by cell-specific targeting and silencing of vagal
pre-ganglionic neurones in the DVMN that contribute to tonic
C-fibre-mediated innervation of the heart.27 In support of our hypoth-
esis, we found that RPc fails to establish cardioprotection when
DVMN neurones are silenced.
In this study, all the experiments were conducted in rats anaesthe-
tized with pentobarbital which is known to suppress chronotropic
vagal tone;26 hence the heart rate in animals subjected to RPc was
not affected by either silencing or optogenetic activation of the
DVMN neurones or in conditions of systemic muscarinic receptor
blockade with atropine. This is consistent with the data demonstrating
that the chronotropic control of the heart is provided predominantly
by a population of vagal pre-ganglionic neurones located in the
nucleus ambiguus.28 Collectively, these data indicate that while an
intact vagal supply is essential for RPc cardioprotection, its beneficial
effect is independent of heart rate modulation as demonstrated by
prior studies involving electrical stimulation of the vagus nerve.5 In
contrast to an earlier view still conveyed by the majority of the physi-
ology textbooks, there is strong evidence that demonstrates function-
al vagal innervation of the ventricles (see for example Lewis et al.29).
Here, we demonstrate that a muscarinic receptor mechanism med-
iates RPc cardioprotection and confirm the existence of a significant
Figure 3 Optogenetic stimulation of DVMN neurones mimics RPc cardioprotection. (A) Representative whole-cell current-clamp recording from
CHIEFtdTomato-expressing DVMN neurone illustrating depolarization and action potential firing in response to blue light (20 ms pulses). Four con-
secutive traces are overlaid. Action potential was elicited in response to 15 out of 16 pulses; (B) DVMN neurones expressing CHIEFtdTomato. Scale
bar ¼ 30 mm. (C) The mean data from voltage-clamp recordings (n ¼ 6) at a holding potential of 250 mV demonstrating the relationship between
duration of the light stimulus and the normalized amplitude of inward current elicited by opening CHIEF channel; (D) optogenetic stimulation of
DVMN neurones reduces myocardial ischaemia/reperfusion injury via a muscarinic receptor-mediated mechanism. Control animals were transduced
to express DsRed in the DVMN. The infarct size is presented as the percentage of area at risk. Individual data and means+ SEM are shown.
**P, 0.01 (Kruskal–Wallis ANOVA by ranks).
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cholinergic supply to the right and left ventricles of the heart in a rat
strain used in this study (Sprague-Dawley) (Supplementary material
online, Figure). These results suggest that an increased efferent
vagal outflow reduces myocardial injury through the potent cardio-
protective effects of acetylcholine (which is as potent as adenosine
in eliciting cardioprotection) reported previously.30–33
The mechanism of RPc-induced cardioprotection was suggested to
involve humoral factor(s) produced during ischemia/reperfusion of
the remote tissue and released into the systemic circulation,34–38
or a neural component,3,37,39–42 or both.37,43 Several studies clearly
demonstrated that RPc cardioprotection requires intact sensory in-
nervation of the peripheral ischaemic tissue.37,39,43 Based on those
data, together with the results of our studies, we proposed the exist-
ence of a ‘remote preconditioning reflex’7 which involves sensory
input from the remote ischaemic organ/tissue and protects the
heart via recruitment of a distinct population of vagal pre-ganglionic
neurones in the DVMN. Indeed, this study demonstrates that the
key component of inter-organ remote protection against ischaemia/
reperfusion injury is neural, since DVMN neurones are essential for
RPc, while their activation (even in the absence of any humoral
factor(s) released from the ischaemic limb) is sufficient to establish
cardioprotection. These results do not exclude the involvement of
humoral factor(s),37,43 but demonstrate that in order to establish car-
dioprotection an enigmatic ‘humoral pathway’ of RPc requires func-
tional integrity of DVMN neurones. Several disparate experimental
models indicate that direct myocardial preconditioning cardioprotec-
tion does not require intact connections between the heart and the
central nervous system. Therefore, the parasympathetic pathway of
myocardial protection described in this report may only be recruited
under certain conditions, for example when RPc stimulus is applied to
the tissue located away from the heart.
Ongoing trials of the efficacy of vagus nerve stimulation in chronic
heart failure patients are expected to confirm the results of the pre-
liminary report showing significant improvements in the quality of life
and left ventricular function.44 Intermittent arm ischaemia in humans
was recently reported to increase parasympathetic tone.45 The
results of the present study obtained with optogenetic stimulation
of DVMN suggest that timely application of the vagus nerve stimula-
tion or other procedures/treatments which reflexly increase vagal ac-
tivity may be highly effective in protecting the heart against acute
lethal ischaemia/reperfusion injury and decreasing morbidity and mor-
tality of patients with ischaemic heart disease.
Figure 4 Muscarinic receptor mechanisms mediate RPc cardio-
protection. RPc was induced by 15 min occlusion of both femoral ar-
teries, followed by 10 min reperfusion. The Sham-RPc procedure
involved the dissection of both femoral arteries without occlusion.
Atropine infusion commenced 15 min prior to RPc or sham-RPc.
RPc conferred no cardioprotection in conditions of systemic mus-
carinic receptor blockade. The infarct size is presented as the per-
centage of area at risk. Individual data and means+ SEM are
shown. **P, 0.01 (Kruskal–Wallis ANOVA by ranks).
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Table 2 Haemodynamic data
Variable Pre-ischaemia End ischaemia Reperfusion (min)
30 60 120
Experiment with systemic muscarinic receptor blockade
Sham-RPc (n ¼ 10) MAP 98+9 98+7 100+7 103+6 106+5
HR 416+12 438+11 421+12 423+9 419+11
RPc (n ¼ 12) MAP 103+4 95+5 97+5 94+4 90+3
HR 427+9 431+7 437+9 436+7 434+7
Atropine + sham-RPc (n ¼ 5) MAP 105+10 92+5 104+2 89+10 81+6
HR 412+12 414+18 410+10 424+11 409+16
Atropine + RPc (n ¼ 7) MAP 107+7 95+7 103+3 103+3 91+5
HR 439+22 437+15 430+11 424+13 413+18
HR, heart rate (min21); MAP, mean arterial blood pressure (mmHg); RPc, remote preconditioning.
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